Jaillon P
Unité de Pharmacologie Clinique, Hôpital Saint-Antoine, Paris, France.
Fundam Clin Pharmacol. 1990;4 Suppl 2:177s-181s.
In order to improve safety for healthy volunteers to be included in phase I clinical trials, a national data bank will be set up and controlled by the French Ministry of Health. Each investigator responsible for an agreed phase I center will have a personal access code to the central computer in order to consult the national registry before including any healthy volunteer in a study. If the volunteer has already participated in a recent study, the investigator will find 2 important pieces of information in the data bank: the duration of the safety period following the preceding trial and during which the subject is not allowed to participate in another study; the total amount of money received by the subject during the last 12 months in grants for phase I studies; this amount will be limited by the Ministry of Health. This healthy volunteer data bank will decrease the risk of drug interaction and will improve safety in phase I trials. However, many practical and ethical problems remain to be solved.
为提高参与I期临床试验的健康志愿者的安全性,法国卫生部将设立并管控一个国家数据库。负责经批准的I期临床试验中心的每位研究人员将拥有中央计算机的个人访问代码,以便在将任何健康志愿者纳入研究之前查阅国家登记册。如果该志愿者最近已经参与过一项研究,研究人员将在数据库中找到两条重要信息:前一项试验后的安全观察期时长,在此期间该受试者不得参与另一项研究;受试者在过去12个月中因I期研究获得的资助总额;这一金额将由卫生部进行限制。这个健康志愿者数据库将降低药物相互作用的风险,并提高I期临床试验的安全性。然而,许多实际和伦理问题仍有待解决。